ROG3 Antibody

What distinguishes IgG3 antibodies from other IgG subclasses at the structural level?

IgG3 antibodies possess several unique structural features that differentiate them from other IgG subclasses. The most notable distinction is the CH2 domain, which has been identified as the major determinant of antibody oligomerization and increased functional affinity to multivalent antigens. The CH2 domain in IgG3 is both glycosylated and atypically charged compared to other IgG subclasses . Additionally, IgG3 has the capacity to form non-covalent oligomers, which is not observed in other mouse IgG subclasses . This oligomerization property contributes to IgG3's enhanced functional capabilities.

Research methodology: To investigate IgG3's unique properties, domain-swapping experiments are highly effective. By generating IgG1/IgG3 hybrid molecules with swapped constant domains, researchers can isolate which domains confer specific functionalities. Functional analyses of these hybrids enable precise determination of which structural elements govern particular antibody properties .

How does the glycosylation pattern of IgG3 affect its functionality?

Methodology for investigation: Researchers can employ enzymatic deglycosylation using PNGase F or similar enzymes to remove N-glycans from purified IgG3 antibodies. The functional properties of deglycosylated antibodies can then be compared with their glycosylated counterparts through binding assays, hemagglutination tests, and complement activation assays to determine glycan-dependent functions.

What molecular mechanisms explain IgG3's increased functional affinity to multivalent antigens?

The increased functional affinity of IgG3 to multivalent antigens results from multiple structural components working in concert. While it has been generally accepted that this increased affinity stems from avidity effects caused by interactions between Fc fragments , research has shown that it is not dependent on a single constant domain. Rather, it is an additive result of discrete properties of all three constant domains (CH1, CH2, and CH3), with CH2 contributing most significantly to the high functional affinity .

Research has shown that introducing IgG3-derived CH1+hinge or CH2 domain into an IgG1 framework enhances antigen binding compared to parental IgG1. Conversely, IgG3 muteins with IgG1-derived CH1+hinge or CH2 demonstrate reduced functional affinity . Among all constant domains, CH2 exerts the strongest influence on antigen binding, with CH2 swapping resulting in IgG3 muteins with 3-12 times decreased functional affinity .

How do IgG3 antibodies recognize antigenically drifted virus variants with greater efficiency than other subclasses?

IgG3 antibodies demonstrate superior capacity to recognize antigenically drifted variants of viruses like influenza and SARS-CoV-2. This enhanced breadth of recognition is particularly evident when the target antigen has undergone mutations that reduce binding affinity . The mechanism appears to involve efficient bivalent binding to low-affinity epitopes on antigenically drifted antigens.

In experimental studies, when IgG subclass-swapped versions of monoclonal antibodies were tested against antigenically distinct viruses (such as H3N2 strains from 2009 and 2016, which differ in HA site E), IgG3 forms showed superior binding and neutralization compared to IgG1 forms . Similarly, with SARS-CoV-2 variants, an IgG3 form of REGN10933 was 100-fold more potent than its IgG1 counterpart in neutralizing Beta (B.1.351) and Omicron (BA.1) variants .

Methodology: Researchers can compare the neutralization capacity of different IgG subclasses by expressing the same variable region in different constant region frameworks and testing against wild-type and variant viruses. Pseudovirus neutralization assays provide a safe and quantitative method for such comparisons.

What types of epitopes are preferentially recognized by IgG3 antibodies?

IgG3 antibodies show remarkable versatility in epitope recognition, with particular effectiveness against glycan structures. Recent research has identified glycan-targeting human IgG3 antibodies with extraordinary breadth of recognition across multiple viral families . These antibodies contain specialized glycan-binding pockets, particularly in the light chain, that recognize complex glycans on antigenic surfaces .

For example, IgG3 antibodies have been identified that bind to diverse antigens including HIV-1 Env, influenza Hemagglutinin, coronavirus spike proteins, hepatitis C virus E protein, Nipah virus F protein, and Langya virus F protein . This glycan-targeting ability appears to be a distinctive feature of certain IgG3 antibodies.

Methodology: LIBRA-seq (linking B cell receptor to antigen specificity through sequencing) has proven valuable for identifying broadly reactive antibodies. This technique allows screening of B cell repertoires against multiple antigens simultaneously, facilitating discovery of broadly reactive antibodies .

What strategies can overcome the reduced half-life of IgG3 antibodies for therapeutic applications?

Despite the superior binding and neutralization properties of IgG3 antibodies against variant antigens, their therapeutic utility is limited by their reduced half-life compared to other IgG subclasses. This shorter half-life is due to decreased affinity for the neonatal Fc receptor and increased susceptibility to proteolytic cleavage .

Engineering approaches can overcome these limitations while retaining IgG3's advantageous properties. For example, researchers have successfully engineered IgG3 antibodies with the R435H mutation to improve protein A binding, an important consideration for antibody purification . This modified IgG3 antibody (IgG3KVH) maintained similar antigen binding as wild-type IgG3 while exhibiting high binding activity for FcγRIIIa and C1q .

Methodology: Antibody engineering techniques such as site-directed mutagenesis can be employed to introduce specific mutations that extend half-life while preserving functional properties. Evaluating engineered variants requires comprehensive characterization including binding kinetics, effector function assays, and in vivo pharmacokinetic studies.

How can IgG3 antibodies be engineered to reduce aggregation during bioprocessing?

Aggregation during bioprocessing is a significant challenge for IgG3 antibodies. Research has identified that the CH3 domain plays a critical role in controlling aggregation under acidic conditions . Specifically, two amino acid substitutions in the CH3 domain, N392K and M397V, have been shown to reduce aggregate formation and increase CH3 transition temperature .

These residues are located within the CH3:CH3 interface and are involved in CH3-CH3 interactions. The M397V substitution is particularly significant as Val397 is part of an aggregation-prone motif found in all IgGs, and introducing this substitution decreased high molecular weight species formation .

Methodology: Differential scanning calorimetry (DSC) provides valuable insights into antibody thermal stability and can quantify improvements in CH3 transition temperature following engineering. Additionally, size-exclusion chromatography can be used to assess aggregate formation under various conditions, including after low pH treatments that mimic viral inactivation steps in manufacturing .

How can the unique properties of IgG3 be transferred to other antibody frameworks for enhanced functionality?

The distinctive properties of IgG3 can be transferred to other antibody frameworks through domain swapping, creating gain-of-function antibodies. Researchers have successfully generated such antibodies by replacing the CH2 domain of IgG1 with that of IgG3 . This approach creates antibodies with improved functional characteristics while potentially avoiding some limitations of native IgG3.

The CH2 domain transfer is particularly effective because this domain has been identified as the major determinant of several key IgG3 properties, including oligomerization, increased functional affinity to multivalent antigens, and efficient complement cascade activation .

Methodology: Domain swapping can be achieved through molecular cloning techniques. The corresponding region encoding the CH2 domain in an IgG1 expression construct is replaced with the sequence encoding the IgG3 CH2 domain. The resulting hybrid antibody can then be expressed in appropriate cell lines and characterized for functional properties compared to parental antibodies.

What role does charge distribution in the CH2 domain play in IgG3 functionality?

While the charge distribution affects functional affinity to antigens, interestingly, antibody oligomerization appears to be independent of CH2 charge . This suggests that different structural features within the CH2 domain govern these distinct functional properties.

Methodology: Site-directed mutagenesis can be used to alter specific charged residues within the CH2 domain. Molecular modeling approaches can guide the selection of residues to mutate based on predicted impacts on charge distribution. The resulting muteins can be characterized through functional affinity assays and oligomerization analysis to determine structure-function relationships.

How might IgG3-skewed vaccination strategies enhance protection against rapidly evolving pathogens?

Given IgG3's superior ability to recognize antigenically drifted variants, developing vaccination strategies that skew antibody responses toward IgG3 could provide better protection against rapidly evolving pathogens like influenza viruses and coronaviruses . Current antibody responses following influenza virus or SARS-CoV-2 infections and vaccinations are typically dominated by IgG1 .

Research suggests that developing new vaccination strategies and adjuvants to skew IgG subclass responses toward IgG3 might be beneficial. This approach could potentially overcome the challenge of antigenic drift by eliciting antibodies with inherently broader reactivity .

Methodology: Adjuvant screening assays can identify formulations that promote IgG3 responses. Animal models can then evaluate the protective efficacy of vaccines that elicit IgG3-dominant responses compared to standard formulations. Human immunological studies would be needed to correlate IgG3 levels with protection against variant strains.

How do germline-reverted IgG3 antibodies compare functionally to their mature counterparts?

Understanding the evolution of broadly reactive IgG3 antibodies can provide insights into how these antibodies develop their unique properties. Research with glycan-targeting IgG3 antibodies has shown that germline-reverted versions retain binding to some antigens (like influenza HA) but lose binding to others (like HIV-1 Env and SARS-CoV-2 spike) .

This suggests that while some binding capabilities exist in the germline configuration, mutations acquired during affinity maturation are essential for the full breadth of reactivity. Even when key residues that form glycan-binding pockets are present in germline sequences, additional somatic mutations appear necessary for binding to certain antigens .

Methodology: Germline reversion studies can be conducted by inferring the germline sequences of antibody variable regions and expressing these constructs for comparison with the mature antibody. Maintaining the CDR3 regions in their mature form while reverting the remainder of the sequence allows evaluation of which somatic mutations are critical for specific binding properties.